A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Trial Profile

A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs TAK 214 (Primary)
  • Indications Norovirus infections
  • Focus Pharmacodynamics
  • Sponsors Takeda
  • Most Recent Events

    • 11 Oct 2018 Planned number of patients changed from 800 to 575.
    • 11 Oct 2018 Planned End Date changed from 30 Dec 2023 to 26 Oct 2021.
    • 11 Oct 2018 Planned primary completion date changed from 30 Dec 2023 to 26 Oct 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top